Search results for "lung cancer"

FCS physicians and senior leaders are co-authors of a study that confirms the effectiveness of trilaciclib for the treatment of adult patients with Extensive-Stage Small Cell Lung Cancer. Trilaciclib is the first FDA-approved therapy in its class to help protect bone marrow cells from damage caused by chemotherapy. Read More

New study on myelosuppression from chemo for small cell lung cancer. Read More

FDA approval of a new immunotherapy treatment improves outcomes for patients with metastatic non small-cell lung cancer. Read More

A study conducted by Florida Cancer Specialists & Research Institute, LLC (FCS) evaluating the use of a new therapy to improve chemotherapy treatment outcomes was published in the October issue of the International Journal of Cancer Care and Delivery. Read More

FCS clinical oncology nutritionist Rhone M. Levin, M.Ed, RDN, CSO, LDN, FAND, is the author of the nutrition chapter featured in the recently published 5th Edition of Lung Cancer Choices. Read More

Fort Myers, Fla., Jan. 12, 2021  — Florida Cancer Specialists & Research Institute (FCS) medical oncologist Michael McCleod, DO, FACOI, who practices in Fort Myers and Cape Coral, is co-author of a recently published study that evaluates and compares best supportive care (BSC) alone versus BSC plus nab-paclitaxel for squamous non-small-cell lung cancer (NSCLC). Published in the January 2021 issue of Clinical Lung Cancer, the study stated that while there have been “… significant treatment advances for patients with advanced non-small-cell lung cancer (NSCLC) …” in recent years, “… the number of treatment options for patients with squamous histologic features has lagged behind that for patients with non-squamous histologic features.” Read More

FCS participates in study for a targeted therapy for the treatment of two cancers Read More

Explore the who, what, where and how much of cancer treatment, and why community oncology matters for patients. Read More

FCS shares what men need to know about prostate, lung and colorectal cancer, including prevention, screening and early detection. Read More

Germline testing can detect inherited DNA variants linked to hereditary cancer, yet testing rates remain critically low. Learn how this testing can improve outcomes, guide treatment, and protect your family. Read More